Roche: positive phase III data in lymphoma
Columvi, in combination with GemOx chemotherapy, demonstrated a statistically significant improvement in overall survival compared to patients treated with MabThera/Rituxan (rituximab) in combination with GemOx.
The safety of the Columvi-GemOx combination appeared consistent with the known profiles of the individual drugs. Data will be submitted to health authorities and shared at a future medical meeting.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction